Denali Therapeutics Inc DNLI

$20.00 -0.53 (-2.58%)

Valuation

Market cap: 3,281,659,000
Revenue TTM: $0
Net income TTM: $-512,540,000
PE ratio: 0.00
Forward PE: —
Profit margin: 0.00%
Debt to equity: 0.00

Trading

Volume: 1,629,500
Avg volume: 1,497,082
Day's range: $19.93 – $20.85
Shares out: 159,847,000
Stochastic %K: 13%
Beta: 1.02
Analysts: Strong Sell
Price target: $35.41

Price

Company profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 866 8547
Website: https://www.denalitherapeutics.com
Address: 161 Oyster Point Boulevard, South San Francisco, United States

Latest news

2026-08-25T12:35:41.000Z · 5 weeks ago

Denali Therapeutics price target raised to $35 from $30 at B. Riley

2026-08-07T13:36:00.000Z · 1 month ago

Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley

2026-08-07T13:06:17.000Z · 1 month ago

Denali Therapeutics price target raised to $34 from $25 at UBS

2026-08-07T11:55:52.000Z · 1 month ago

Denali Therapeutics price target raised to $34 from $31 at Baird

2026-08-06T20:11:31.000Z · 1 month ago

Denali Therapeutics reports Q2 EPS (68c), consensus (47c)

Aug 6, 2026, 4:01 PM EDT · 1 month ago

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

2026-08-03T14:00:55.000Z · 2 months ago

Denali Therapeutics treatment of frontotemporal dementia granted orphan status

Jul 27, 2026, 4:01 PM EDT · 2 months ago

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

2026-07-23T12:56:08.000Z · 2 months ago

Denali Therapeutics price target raised to $36 from $35 at Morgan Stanley

2026-07-16T08:25:08.000Z · 2 months ago

Denali Therapeutics price target raised to $35 from $31 at Deutsche Bank

2026-07-14T16:05:47.000Z · 2 months ago

Denali Therapeutics falls -14.1%

2026-07-14T14:05:10.000Z · 2 months ago

Denali Therapeutics falls -12.4%

2026-07-13T12:05:08.000Z · 2 months ago

Denali Therapeutics price target raised to $26 from $20 at Wedbush

2026-07-13T09:50:38.000Z · 2 months ago

Denali Therapeutics resumed with an Overweight at JPMorgan

Jul 9, 2026, 4:01 PM EDT · 2 months ago

Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

2026-06-18T12:14:55.000Z · 3 months ago

Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV

Jun 18, 2026, 8:00 AM EDT · 3 months ago

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

2026-05-22T18:35:52.000Z · 4 months ago

Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley

2026-05-22T13:31:04.000Z · 4 months ago

Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank

2026-05-21T22:35:11.000Z · 4 months ago

Denali Therapeutics trading resumes

2026-05-21T22:05:12.000Z · 4 months ago

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

BIIB

2026-05-21T21:55:12.000Z · 4 months ago

Denali Therapeutics trading halted, news pending

2026-05-14T16:46:35.000Z · 4 months ago

Denali Therapeutics price target lowered to $40 from $42 at Morgan Stanley

May 7, 2026, 4:01 PM EDT · 4 months ago

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Apr 3, 2026, 1:30 PM EDT · 6 months ago

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Mar 25, 2026, 11:50 AM EDT · 6 months ago

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

Mar 6, 2026, 11:33 AM EST · 7 months ago

FDA reversals leave investors worrying about the fates of other experimental drugs

MRNA RGNX WVE

Feb 26, 2026, 4:01 PM EST · 7 months ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Feb 5, 2026, 2:00 PM EST · 7 months ago

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Feb 2, 2026, 8:00 AM EST · 8 months ago

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Jan 29, 2026, 4:00 PM EST · 8 months ago

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Dec 30, 2025, 8:00 AM EST · 9 months ago

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Dec 10, 2025, 12:14 AM EST · 9 months ago

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Dec 9, 2025, 4:01 PM EST · 9 months ago

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Dec 4, 2025, 7:00 AM EST · 10 months ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

RPRX

Nov 6, 2025, 4:01 PM EST · 11 months ago

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 13, 2025, 4:01 PM EDT · 11 months ago

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Aug 12, 2025, 9:47 AM EDT · 1 year ago

The Best Small-Cap Stocks to Buy Now

KYMR WAY

Aug 11, 2025, 4:01 PM EDT · 1 year ago

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 7, 2025, 8:00 AM EDT · 1 year ago

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

May 6, 2025, 4:01 PM EDT · 1 year ago

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

Apr 2, 2025, 8:00 AM EDT · 1 year ago

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Mar 27, 2025, 7:40 AM EDT · 1 year ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN GPCR INSM MRK SWTX

Feb 27, 2025, 4:01 PM EST · 1 year ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 6, 2025, 11:42 AM EST · 1 year ago

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Jan 6, 2025, 4:43 PM EST · 1 year ago

Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:30 PM EST · 1 year ago

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Nov 6, 2024, 4:01 PM EST · 1 year ago

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Sep 3, 2024, 8:00 AM EDT · 2 years ago

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Aug 14, 2024, 2:00 PM EDT · 2 years ago

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Aug 1, 2024, 6:45 AM EDT · 2 years ago

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Jun 3, 2024, 8:00 AM EDT · 2 years ago

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

May 7, 2024, 4:01 PM EDT · 2 years ago

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 8:00 AM EDT · 2 years ago

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Feb 27, 2024, 8:05 AM EST · 2 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 27, 2024, 8:00 AM EST · 2 years ago

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Feb 7, 2024, 8:00 AM EST · 2 years ago

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Feb 1, 2024, 8:00 AM EST · 2 years ago

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Jan 8, 2024, 8:00 AM EST · 2 years ago

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Nov 7, 2023, 4:01 PM EST · 2 years ago

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Sep 11, 2023, 6:30 AM EDT · 3 years ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

FHTX MCRB MRNA SANA

Aug 30, 2023, 8:30 AM EDT · 3 years ago

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Aug 8, 2023, 4:01 PM EDT · 3 years ago

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jun 21, 2023, 6:00 AM EDT · 3 years ago

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

FHTX MCRB MRNA SANA

Jun 20, 2023, 7:00 AM EDT · 3 years ago

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

May 8, 2023, 4:01 PM EDT · 3 years ago

Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 12, 2023, 8:00 AM EDT · 3 years ago

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

Apr 10, 2023, 8:00 AM EDT · 3 years ago

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

Feb 27, 2023, 4:01 PM EST · 3 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Stocktwits

flowerchefstocks Sep 21, 10:12 PM

$DNLI Looks like there is another Orphan Drug candidate that could become a licensing deal. https://www.streetwisereports.com/article/2026/09/21/medicuss-pfizer-deal-was-not-a-fire-sale-a-strategic-bet-on-de-risked-adc-drug.html Hope these valuations continue to hold.

0 replies